Doxefazepam

Doxefazepam

Doxefazepam (marketed under brand name Doxans) is a International Agency for Research on Cancer's (IARC) IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."[4]

See also

References

  1. ^ DE Patent 2338058 - BENZODIAZEPINVERBINDUNGEN FUER DIE THERAPIE
  2. ^ Rodriguez, G; Rosadini, G; Sannita, WG; Strumia, E (1984). "Effects of doxefazepam on normal sleep. An EEG and neuropsychological study". Neuropsychobiology 11 (2): 133–9.  
  3. ^  
  4. ^  

External links

  • Inchem.org - Doxefazepam
  • IARC Monographs - Doxefazepam